Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1991-4-2
|
pubmed:abstractText |
This study examined the fate of vascularized muscle allografts using a genetically defined rat model. Its purposes were (1) to analyze the histologic/immunologic responses, (2) to study the effect of cyclosporine on graft survival, and (3) to examine the possibility of inducing tolerance. In rats differing at a major histocompatibility locus, vascularized gastrocnemius muscle transplants were performed based on the sural branches of the femoral artery and vein. Forty-two animals studied were divided into three groups: Group 1, allografts, was treated without cyclosporine; Group 2, allografts, was administered continuous cyclosporine; and Group 3, allografts, was administered cyclosporine for 6 weeks only. Evaluation consisted of gross examination, H&E histology, and immunologic studies (MLC, CML, and complement-dependent 51Cr lysis assay). Lytic units (LU) were derived from the assays and served as the indicator of immune response. Group 1 animals had uniform rejection with intense cell-mediated response (LU 23 to 47) and low humoral response. Group 2 animals had viable allografts throughout with suppressed lytic unit values of 0 to 9 initially, which rose to 14 to 29 at 6 weeks despite continuous cyclosporine treatment. Group 3 animals showed rejection similar to the untreated animals. Autografts were performed as controls and survived indefinitely. Analysis of variance was significant at p less than 0.05. Using a reliable rat model for vascularized muscle allografts, we found that in transplantation across a major histocompatibility barrier, the initial immune response was primarily cell-mediated. Cyclosporine suppressed rejection only when given continuously, and short-term cyclosporine treatment did not induce a tolerant state. These data should be useful for future studies of vascularized muscle allografts.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0032-1052
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
87
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
412-8
|
pubmed:dateRevised |
2011-2-16
|
pubmed:meshHeading |
pubmed-meshheading:1825516-Animals,
pubmed-meshheading:1825516-Cyclosporins,
pubmed-meshheading:1825516-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:1825516-Graft Survival,
pubmed-meshheading:1825516-Hindlimb,
pubmed-meshheading:1825516-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:1825516-Major Histocompatibility Complex,
pubmed-meshheading:1825516-Muscles,
pubmed-meshheading:1825516-Rats,
pubmed-meshheading:1825516-Rats, Inbred BN,
pubmed-meshheading:1825516-Rats, Inbred Lew,
pubmed-meshheading:1825516-Transplantation, Isogeneic
|
pubmed:year |
1991
|
pubmed:articleTitle |
Vascularized muscle allografts and the role of cyclosporine.
|
pubmed:affiliation |
Orthopedic Research Laboratory, Johns Hopkins Hospital, Baltimore, Md.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|